ICON Public Limited Company
ICLRHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeHeadquartered within the healthcare sector, ICON Public Limited Company focuses on Diagnostics & Research services and products. ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. At a $12.72B market cap, ICON Public Limited Company ranks as a large-cap company within healthcare. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Market Cap
$12.72B
Beta
1.20
P/E (TTM)
257.58
P/E (Fwd)
13.88
EPS (TTM)
$0.64
EPS (Fwd)
$11.88
ROE
0.3%
ROA
1.0%
Cash
$928.4M
Total Debt
$3.53B
Free CF
$622.6M
52W Change
-2.4%
Annual Financials
Cash vs Debt
Where ICLR stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, ICLR finished 20.94% above its 150-day moving average ($136.42) and 11.94% above its 200-day moving average ($147.39). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ICLR overbought or oversold?
At the September 1, 2026 close, ICLR's RSI(14) was 49.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, ICLR has $928.4M in cash with $3.53B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $622.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 0.3%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.0% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $7.74B (2022) to $8.25B (2025).
At over 50x earnings, ICLR carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. No single metric tells the full story. Reviewing ICLR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.